HOME >> BIOLOGY >> NEWS
New predatory dog-sized dinosaur unearthed on Madagascar

Fossilized remains of a bizarre, dog-sized predatory dinosaur were recently recovered on the island of Madagascar.

The discovery, funded in part by the National Science Foundation (NSF), was announced this week in the journal Nature by a team of researchers led by paleontologist Scott Sampson of the University of Utah. Matthew Carrano and Catherine Forster from the State University of New York at Stony Brook co-authored the paper.

These fossils, which date to the Late Cretaceous period (about 65-70 million years ago), represent a dinosaur new to science, dubbed Masiakasaurus knopfleri. Masiakasaurus was relatively small, as dinosaurs go, with a total body length of 1.6-2.0 meters, much of which consisted of its long neck and tail. The total mass of this small carnivore would have been approximately 35 kilograms (80 lbs.), roughly that of a German Shepherd dog.

"Scott Sampson and the NSF-supported team of U.S. scientists working in Madagascar continue to reveal startling new vertebrate fossils," says H. Richard Lane, geology and paleontology program director in NSF's division of earth sciences, which funded the research. "Masiakasaurus is one of several such recent discoveries by this prolific team, with, I'm sure, more to come."

Masiakasaurus is based on a number of isolated bones from several individuals. The great majority of these fossils were recovered from a single site. Included in the collection are parts of the jaws and about 40 percent of the remainder of the skeleton, with some bones being represented by multiple examples.

The most bizarre aspect of this theropod dinosaur is its extremely specialized teeth and jaws. The first tooth of the lower jaw is oriented almost horizontally, projecting forward instead of upward. Subsequent teeth angle increasingly upward until the sixth tooth; from this point backward, all the teeth point straight up. The teeth themse
'"/>

Contact: Cheryl Dybas
Cdybas@nsf.gov
703-292-8070
National Science Foundation
22-Jan-2001


Page: 1 2 3

Related biology news :

1. A bizarre new predatory dinosaur unearthed on Madagascar
2. Computer imaging of Archeopteryx skull suggests this dinosaur-bird link could fly
3. Two dinosaurs from Africa give clues to continents split
4. A lost world: Two previously unknown dinosaurs discovered in Antarctica
5. Princeton paleontologist produces evidence for new theory on dinosaur extinction
6. Is this what killed the dinosaurs?
7. New study suggests missing link that explains how dinosaurs learned to fly
8. Seven-foot living dinosaur lurks in Oregon
9. Scientist says ostrich study confirms bird hands unlike those of dinosaurs
10. Cosmic impacts implicated in both the rise and fall of dinosaurs
11. New dinosaur related to Triceratops

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New predatory dog sized dinosaur unearthed Madagascar

(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
(Date:5/30/2015)... May 30, 2015 CTI BioPharma Corp. (CTI ... business (NYSE: BAX ) today announced data from ... pacritinib for the treatment of myelofibrosis – in a ... of the American Society of Clinical Oncology (ASCO), May ... Pacritinib is an investigational oral multikinase inhibitor with ...
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/30/2015)... Texas , May 30, 2015  Caris ... from a study in which researchers identified biomarker ... metachronous paired glioma tumors, indicating changes in response ... observing 19 patients was a subset of a ... molecular heterogeneity of the cancer. These data utilizing ...
(Date:5/29/2015)... CHAPEL HILL, N.C. , May 29, 2015 ... the medical affairs function into roles involving clinical ... As its responsibilities have grown, Medical Affairs ... the function as a global group. And while ... sometimes find it challenging to identify strong performance ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2
Cached News: